Anzeige
❌
Mehr »
Samstag, 07.11.2026 - Börsentäglich über 12.000 News
Was passiert, wenn Tiefseebergbau funktioniert? Der von Anlegern übersehene Ripple-Effekt
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: 853849 | ISIN: JP3463000004 | Ticker-Symbol: TKD
Tradegate
06.11.26 | 21:05
37,120 Euro
-0,43 % -0,160
Branche
Chemie
Aktienmarkt
Japan 225
Singapur
1-Jahres-Chart
TAKEDA PHARMACEUTICAL CO LTD Chart 1 Jahr
5-Tage-Chart
TAKEDA PHARMACEUTICAL CO LTD 5-Tage-Chart
RealtimeGeldBriefZeit
37,07037,48011:01
37,11037,48006.11.

Aktuelle News zur TAKEDA PHARMACEUTICAL Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
FrTakeda Pharmaceutical Co President Trades $1.16M In Company Stock9
TAKEDA PHARMACEUTICAL Aktie jetzt für 0€ handeln
30.10.Fierce Pharma Asia-The hunt for Enhertu's successor; ESMO data from Merck, BMS, Takeda and more11
29.10.Takeda Beats Earnings Forecasts and Hikes Outlook Despite Generic Overhang18
29.10.Takeda outlines JPY 1.19T FY 2026 core operating profit forecast while targeting early November U.S. ORZEYFUL launch9
29.10.Takeda raises its profit forecast, but core earnings per share fell 1.2% at constant currency7
29.10.Takeda FY2026 Q2 slides: new medicines set growth trajectory5
29.10.Takeda Pharmaceutical Co Q2 2026 Earnings Call Transcript6
29.10.Takeda H1 EPS Surges, Revenue Up 8.4%; Upgrades FY26 Outlook409TOKYO (dpa-AFX) - Takeda Pharmaceutical Company Ltd. (TAK), Thursday reported a 171.8 percent surge in first half earnings compared to the prior year. Looking ahead to the full year 2026, the...
► Artikel lesen
29.10.TAKEDA PHARMACEUTICAL CO LTD - 6-K, Report of foreign issuer5
29.10.TAKEDA PHARMACEUTICAL COMPANY LIMITED: FINANCIAL STATEMENTS AND RELATED ANNOUNCEMENT::HALF YEARLY RESULTS14
29.10.Takeda Pharmaceutical Company Limited H1 Profit Climbs354TOKYO (dpa-AFX) - Takeda Pharmaceutical Company Limited (TAK) announced earnings for its first half that Increased, from the same period last yearThe company's earnings came in at JPY305.626...
► Artikel lesen
29.10.Takeda Pharmaceutical Non-GAAP EPS of ¥308.00, revenue of ¥2407B; upgrades FY 2026 outlook11
29.10.Takeda Pharmaceutical Company Limited: Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones862ORZEYFULTM approved in the U.S., Japan and China for narcolepsy type 1 (NT1), MIMRYLOTM launched in the U.S. for erythrocytosis in polycythemia vera (PV) Zasocitinib advances to U.S. Food...
► Artikel lesen
28.10.Takeda Pharmaceutical Q2 Earnings Preview8
23.10.ESMO26: Takeda preps filings on CLDN18.2 gastric cancer data6
23.10.ESMO: Takeda's $1.2B bet on Innovent 'absolutely' pays off with details of ADC's phase 3 win10
23.10.Takeda reports positive phase 3 trial results for gastric cancer drug10
23.10.Takeda meldet positive Phase-3-Ergebnisse für Magenkrebs-Wirkstoff10
19.10.Takeda Reports Positive New Data Of VERDICT Phase 4 ENTYVIO Trial In Ulcerative Colitis911TOKYO (dpa-AFX) - Japan's Takeda Pharmaceutical Co. Ltd. (TAK,4502.T) announced Monday positive new data from VERDICT (NCT04259138), a Phase 4 ENTYVIO clinical trial, in ulcerative colitis or...
► Artikel lesen
16.10.H.C. Wainwright reiterates Halozyme stock rating on Takeda trial data44
1 2 3 4 5 Weiter >>
177 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1